In October, due to demand from existing healthcare partners, CTS began testing blood donors for antibody to Babesia microti under an Investigational New Drug exemption as a release test.
By the end of 2017, CTS has secured three source plasma partners and continues to seek additional pa...
CTS Tampa lab implements Dengue testing on behalf of a healthcare partner in an endemic area.
In August CTS begins source plasma testing as a new line of business to one of the largest plasma fr...
In April, CTS becomes the first blood donor testing organization in the US to implement Zika testing...
CTS embraces a company-wide operational excellence initiative designed to change the culture to enha...
In January, CTS is incorporated as a non-profit organization owned by Vitalant and OneBlood (formerl...